Retrospective analysis of the efficacy of adjuvant CIK cell therapy in epithelial ovarian cancer patients who received postoperative chemotherapy
Retrospective analysis of the efficacy of adjuvant CIK cell therapy in epithelial ovarian cancer patients who received postoperative chemotherapy
复制标题
CIK细胞辅助治疗对上皮性卵巢癌术后化疗患者的疗效回顾性分析
DOI：
10.1080/2162402x.2018.1528411
复制
发表时间：
2018-11
期刊：
影响因子：
7.2
通讯作者：
Zheng Min
中科院分区：
文献类型：
--
作者：
Zhou Yun;Chen Chang-long;Jiang Sen-wei;Feng Yanling;Yuan Linjing;Chen Ping;Zhang Lan;Huang Shuting;Li Jundong;Xia Jian-Chuan;Zheng Min
摘要细胞因子诱导的杀伤细胞（CIK）已被证明在体外和体内对卵巢癌细胞具有强效的溶细胞作用。然而，CIK细胞维持疗法在上皮性卵巢癌（EOC）患者中一线治疗后的临床疗效仍不清楚。本研究回顾性分析了646例EOC术后患者，其中72例接受化疗和序贯免疫治疗（CIT组），574例仅接受化疗（对照组）。CIT组患者接受至少4个周期的CIK细胞输注（范围8.0 × 109 ~ 1.3 × 1010个细胞），每个周期间隔2周。生存分析显示，与对照组相比，CIT组的总生存（OS）率显著更高，以及有利的无进展生存（PFS）。单因素和多因素分析表明，辅助CIT是EOC患者OS的独立预后因素。此外，亚组分析显示，辅助CIT显著改善了年龄大于45岁、CA 125 ≤ 1000或中度或低分化肿瘤患者的OS，并延长了残留病变> 1 cm患者的PFS。此外，Kaplan-Meier分析显示，输注的CIK细胞中较高比例的CD 3 + CD 8 +/CD 3 + CD 56+表型或较低百分比的CD 3 + CD 4 +/CD 3 − CD 56+表型与EOC患者的较好生存率显著相关。此外，在CIT组的CIK细胞免疫治疗的所有过程中，12.5%（9/72）的患者发生了1级或2级的自限性低热和寒战。未记录免疫治疗相关严重反应。这些数据表明，CIK细胞辅助CIT是延长EOC患者生存期的有效治疗方法。
ABSTRACT Cytokine-induced killer (CIK) cells are demonstrated to possess potent cytolytic effect against ovarian cancer cells in vitro and in vivo. However, the clinical efficacy of maintenance therapy of CIK cells in patients with epithelial ovarian cancer (EOC) after first-line treatment remains unclear. This retrospective study included 646 cases of postoperative EOC patients, 72 of which received chemotherapy and sequential immunotherapy (CIT group), and 574 of which received only chemotherapy (Control group). Patients in the CIT group received at least four cycles of CIK cell (range 8.0 × 109 – 1.3 × 1010 cells) transfusion, with the interval of each cycle being 2 weeks. Survival analysis showed a significantly higher overall survival (OS) rate in the CIT group compared with the control group, as well as a favorable progression-free survival (PFS). Univariate and multivariate analyses indicated that adjuvant CIT was an independent prognostic factor for the OS of patients with EOC. Furthermore, subgroup analyses showed that adjuvant CIT significantly improved the OS of patients older than 45 years, with CA125 ≤ 1000, or with moderate or poorly differentiated tumors, and prolonged the PFS of patients with residual disease > 1 cm. Additionally, Kaplan-Meier analyses revealed that a higher fraction of CD3+CD8+/CD3+CD56+ phenotypes or lower percentage of CD3+CD4+/CD3−CD56+ phenotypes in the infused CIK cells significantly associated with better survival of patients with EOC. Furthermore, across all processes of CIK cell immunotherapy in the CIT group, 12.5% (9/72) of patients developed self-limiting light fevers and shivering at grade 1 or 2. No immunotherapy-related serious reactions were recorded. These data indicate that adjuvant CIT with CIK cells is an effective therapeutic approach to prolonging the survival of EOC patients.
登录
查看更多内容
影响因子：
2.8
作者：
C. Lum;C. Steer
通讯作者：
C. Lum;C. Steer
DOI：
10.1084/jem.174.1.139
发表时间：
1991-07-01
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Schmidt-Wolf IG;Negrin RS;Kiem HP;Blume KG;Weissman IL
通讯作者：
Weissman IL
DOI：
10.1891/9780826121646.0002
发表时间：
2018-09
期刊：
Cancer Rehabilitation
影响因子：
--
作者：
K. Miller;R. Siegel;R. Khan;A. Jemal
通讯作者：
K. Miller;R. Siegel;R. Khan;A. Jemal
影响因子：
10.1
作者：
Introna, Martino;Borleri, Gianmaria;Rambaldi, Alessandro
通讯作者：
Rambaldi, Alessandro
影响因子：
82.9
作者：
Crome SQ;Nguyen LT;Lopez-Verges S;Yang SY;Martin B;Yam JY;Johnson DJ;Nie J;Pniak M;Yen PH;Milea A;Sowamber R;Katz SR;Bernardini MQ;Clarke BA;Shaw PA;Lang PA;Berman HK;Pugh TJ;Lanier LL;Ohashi PS
通讯作者：
Ohashi PS